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Should adrenaline be used in 
patients with hemodynamically 
stable anaphylaxis? Incident case 
control study nested within a 
retrospective cohort study
Byuk Sung Ko1,*, Ji Yeon Kim1,*, Dong-Woo Seo1, Won Young Kim1, Jae Ho Lee1,2, Aziz Sheikh3 
& David W. Bates4
Although adrenaline (epinephrine) is a cornerstone of initial anaphylaxis treatment, it is not often used. 
We sought to assess whether use of adrenaline in hemodynamically stable patients with anaphylaxis 
could prevent the development of hypotension. We conducted a retrospective cohort study of 761 adult 
patients with anaphylaxis presenting to the emergency department (ED) of a tertiary care hospital over 
a 10-year period. We divided the patients into two groups according to the occurrence of hypotension 
and compared demographic characteristics, clinical features, treatments and outcomes. Of the 340 
patients with anaphylaxis who were normotensive at first presentation, 40 patients experienced 
hypotension during their ED stay. The ED stay of the hypotension group was significantly longer than 
that of patients who did not experience hypotension (496 min vs 253 min, P = 0.000). Adrenaline use 
in hemodynamically stable anaphylaxis patient was independently associated with a lower risk of 
developing in-hospital occurrence of hypotension: OR, 0.254 [95% CI, 0.091–0.706]. Adrenaline use 
in hemodynamically stable anaphylaxis patients was associated with a reduced risk of developing 
in-hospital occurrence of hypotension. Adverse events induced by adrenaline were rare when the 
intramuscular route was used.
Anaphylaxis is a serious, potentially fatal, systemic allergic reaction that develops rapidly after exposure to an 
offending agent1. The lifetime prevalence of anaphylaxis has been reported to be between 0.5–2%. The most com-
mon causes are drugs, foods and insect venom2–5. Recent studies have shown that the incidence of anaphylaxis is 
increasing in many countries6. Therefore, the prevention and treatment of anaphylaxis is important.
All major guidelines indicate that adrenaline (epinephrine) is the first-line recommended treatment in those 
experiencing anaphylaxis7–11. Delayed use of adrenaline has been shown to be associated with increased severity 
of reactions and fatalities12–14. However, various researches have consistently shown that adrenaline is under-used 
by physicians15–17. There are many reasons for this phenomenon. These include lack of physician’s knowledge 
about the presentation and recognition of anaphylaxis and fear of inducing adrenaline associated cardiovascu-
lar side-effects18–21. This happens more frequently particularly when patients initially present as normotensive 
because some practitioners still think that ‘shock’ needs to be present for a diagnosis of anaphylaxis22. Studies have 
however found that many cases of anaphylaxis do not manifest with cardiovascular shock; indeed, when it occurs 
anaphylactic shock is associated with particularly poor outcome and a high risk of fatality23–25.
We sought to investigate whether adrenaline use in hemodynamically stable patients can prevent the 
in-hospital occurrence of hypotension in hemodynamically stable patients with anaphylaxis.
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Results
During the study period, 761 patients presented to the emergency department (ED) and were given a discharge 
diagnosis related to anaphylaxis. Of these, we excluded 126 patients whose diagnosis was not compatible with 
our pre-specified population and anaphylaxis definition criteria. The reasons for exclusion were: 176 patients 
with hypotension as an initial presentation at hospital after symptom onset, 62 patients younger than 16 years; 57 
patients who were transferred from another hospital or to another hospital. We were thus left with a total of 340 
hemodynamically stable (defined as systolic blood pressure ≥ 90 mmHg) patients with anaphylaxis in the final 
analysis (Fig. 1). The mean age was 45.6 ± 15.3 years and 52.1% were female. During their ED stay, 40 patients 
(11.8%) developed hypotension. The median time from first medical contact at hospital to the occurrence of 
hypotension was 35.0 (interquartile range (IQR) 9.0–116.0) minutes. The demographic characteristics, comorbid-
ities, symptoms, signs and initial vital signs of the patients who developed hypotension versus those who did not 
are summarized in Table 1. Comorbidities, allergy history and anaphylaxis history were not significant different 
between the two groups. The initial systolic and diastolic blood pressures (BP) at first medical contact of patients 
who developed hypotension were significantly lower than those of patients who did not develop hypotension 
(114.1 vs 129.3 P = 0.000, 70.3 vs 81.1 P = 0.020, respectively).
No mortality was observed in ether group. The length of ED stay in the hypotension group was significantly 
longer than those of patients who did not experience hypotension (496 min vs 253 min, P < 0.001). In addition, a 
higher admission rate was observed in those experiencing hypotension when compared to those who remained 
normotensive (40% vs 15.7%, P = 0.001). Treatments between the two groups did not show any significant dif-
ference except for use of adrenaline in hemodynamically stable anaphylaxis patient (Table 2). Adrenaline use in 
hemodynamically stable anaphylaxis patient was less frequent in the hypotensive group (P = 0.010).
A stepwise logistic regression analysis with backward elimination was performed to identify independent vari-
ables that could predict hypotension development. Adrenaline use in hemodynamically stable anaphylaxis patient 
was associated with a reduced risk of developing hypotension (OR, 0.254 [95% CI, 0.091–0.706]) (Table 3).
There were two adrenaline induced adverse events. One patient was a 44 year old man, who presented with 
urticaria and dyspnea after taking ibupropen. He complained of chest discomfort after three minutes of receiv-
ing 0.1 mg adrenaline intravenous injection (whether dilution was performed or not was not confirmed) before 
development of hypotension. But it disappeared immediately after cessation of adrenaline and there were no 
abnormality on electrocardiogram and cardiac biomarkers. Another person was a 61 year old man with urticaria 
and hypotension. Adrenaline was administered after hypotension. Frequent ventricular premature beats were 
observed on his electrocardiogram after 0.1mg adrenaline intravenous injection (dilution was performed); he did 
not experience any symptoms. There was no cardiac biomarker elevation or any other adrenaline related adverse 
event.
Discussion
Adrenaline use was associated with reduced risk of developing hypotension in patients experiencing anaphylaxis 
who were normotensive on presentation to hospital.
Figure 1. Patient flow diagram. 
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(n = 40) P Value
Demographic factor 
 Age, years 46.0 ± 15.5 42.7 ± 13.9 0.208
 Male sex 145 (48.3) 18 (45.0) 0.738
Comorbidity
 Hypertension 39 (13.0) 5 (12.5) 1.000
 Diabetes mellitus 11 (3.7) 0 (0.0) 0.374
 Cardiac disease 14 (4.7) 3 (7.5) 0.705
 Neoplasm 29 (9.7) 5 (12.5) 0.781
 CKD 2 (0.7) 1 (2.5) 0.314
 Bronchial asthma 13 (4.3) 1 (2.5) 1.000
 History of allergy 109 (36.3) 13 (32.5) 0.727
 History of anaphylaxis 25 (8.3) 3 (7.5) 1.000
Symptoms and Signs
 Mucocutaneous 261 (87.0) 34 (85.0) 0.803
 Cardiovascular 110 (36.7) 17 (42.5) 0.490
 Pulmonary 203 (67.7) 24 (60.0) 0.373
 Gastrointestinal 93 (31.0) 19 (47.5) 0.048
 Neurologic 63 (21.0) 21 (52.5) 0.000
Trigger
 Drug 75 (25.0) 20 (50.0) 0.001
 Contrast media 48 (16.0) 3 (7.5) 0.236
 Food 106 (35.3) 10 (25.0) 0.218
 Insect venom 18 (6.0) 2 (5.0) 1.000
 Contact 4 (1.3) 1 (2.5) 0.467
 Idiopathic 47 (15.7) 4 (10.0) 0.480
 Severe on severity Gradea 48 (16.0) 9 (22.5) 0.365
Initial vital signs
 Systolic BP, mmHg 129.3 ± 23.4 114.1 ± 24.7 0.000
 Diastolic BP, mmHg 81.1 ± 17.3 70.3 ± 27.7 0.020
 Heart rate, beats/min 90.9 ± 21.4 88.8 ± 23.2 0.562
 Respiratory rate, breaths/min 21.6 ± 3.6 22.9 ± 5.7 0.170
 Oxygen saturation, % 97.5 ± 2.6 96.3 ± 3.6 0.052
Table 1.  Baseline characteristics and clinical features of anaphylaxis patients according to the development 
of hypotension. CKD: chronic kidney disease; BP: blood presssure. Values are expressed as mean ± SD, n (%). 
aSevere was defined as cyanosis or SpO2 ≤ 92%, hypotension (systolic BP < 90 mm Hg), confusion, collapse, loss 










 H1-antihistamines 269 (89.7) 37 (92.5) 0.781
 H2-antihistamines 255 (85.3) 37 (92.5) 0.239
 Corticosteroids 243 (81.0) 35 (87.5) 0.389
 Auto injector 6 (2.0) 0 (0.0) 1.000
 Salbutamol nebulizer 55 (18.3) 5 (12.5) 0.393
Use of adrenaline in 
hemodynamically stable 101 (33.7) 5 (12.5) 0.010
Admission 47 (15.7) 16 (40.0) 0.001
ED stay, minutes 253 (152–404) 496 (246–821) 0.000
Medical contact to 
hypotension 35.0 (9.0–116.0) NA
Table 2.  Treatments and outcomes of anaphylaxis patients according to the development of hypotension. 
ED: emergency department; NA: nonapplicable. Values are expressed as median and interquartile range (IQR), 
or n (%).
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There were only two adrenaline induced adverse events, and neither resulted in permanent harm. Both were 
associated with the intravenous route and were thus used against guideline recommendations which clearly 
state that the intramuscular route is the preferred option. Clearly, adrenaline would have to be used with care in 
patients with underlying cardiac disease, but it appears that it is being underused in patients with anaphylaxis, 
and that higher rates of use has the potential to improve outcomes in this group.
To our knowledge, no study to date has reported association between use of adrenaline and the occurrence 
of hypotension in anaphylaxis. To date, adrenaline use for anaphylaxis has been largely based on expert opinion 
and relatively weak evidence; in particular, there have been no controlled trials and given the ethical and logistical 
challenge to mounting these in anaphylaxis these are unlikely to be forthcoming21,22. We have therefore we believe 
undertaken as rigorous a study as is possible at the present time.
Confounding by indication needs to be considered, although drug-induced anaphylaxis was more prevalent in 
the hypotension group, there was no difference in the severity between the two groups at initial presentation. That 
said, in the absence of undertaking a randomized controlled trial we cannot be sure that adrenaline prevented the 
development of hypotension. A randomized, controlled trial would be the best approach for addressing this issue. 
Although it has been reported that prophylactic use of adrenaline can substantially reduce the risk of anaphylaxis 
with anti-snake venom26, we did not find similar results with our study.
The primary outcome was defined as the development of hypotension during ED stay because mortality with 
anaphylaxis is mainly due to cardiovascular and respiratory compromise14. Hypotension reflects a severe general-
ized hypersensitivity reaction and is associated with poor outcomes27. Additionally, in our study, the hypotension 
group showed a longer ED stay and higher admission rate than the normotensive group due to stabilization of 
anaphylaxis and observation for more fatal reactions. Furthermore, the definition of respiratory compromise is 
difficult because there is no definite and objective parameter that reflects respiratory compromise in anaphylaxis. 
In contrast, cardiovascular compromise can be easily assessed by measurement of blood pressure and is relatively 
objective.
The main limitation of our present study was its retrospective study design. Accordingly, important infor-
mation concerning clinical symptoms and past history of allergies or anaphylaxis and other factors may have 
been omitted. We could only trace the course and outcomes of patients in the ED, so there is a chance that the 
development of hypotension or significant biphasic reaction was missed. However, recent studies reported that 
clinically significant biphasic reactions in anaphylaxis are quite rare, so it is unlikely that mortality or a significant 
biphasic reaction including hypotension was underestimated28,29. Our study showed a small difference in triggers 
and clinical features compared with preexisting studies, so it might be difficult to generalize our results to all kinds 
of anaphylaxis situations. Further prospective studies are warranted.
Not all anaphylaxis symptoms and signs occur simultaneously. In some cases, anaphylaxis symptoms begin 
as a minor form, progressing so rapidly that no treatment can be given before respiratory or cardiac arrest14. 
Sampson et al.23 reported on fatal and near-fatal anaphylactic reactions to food in children and adolescents. Most 
of the patients presented skin and abdominal symptoms after 1 to 30 min that became severe between 20 min 
and 2.5 h later. The most important difference between fatal and nonfatal patients was that no patient in the 
fatal group received adrenaline before severe symptoms developed, whereas all patients with nonfatal reactions 
received adrenaline before or within 5 min of the development of severe symptoms. This clinical manifestation of 
anaphylaxis can be found in clinical practice. Thus, early administration of adrenaline should be considered, even 
if the first presentation is a mild form of anaphylaxis.
Adrenaline decreases mucosal edema, relieves upper airway obstruction, and increases blood pressure via 
an alpha-1 adrenergic vasoconstrictor effect. Beta-1 and -2 adrenergic receptor-mediated effects of adrenaline 
lead to inotropic and chronotropic effects and bronchodilation, which have beneficial effects in patients in ana-
phylaxis20,21. However, adrenaline also has adverse effects, from mild (i.e., pallor, tremor, anxiety, palpitations, 
headache, and dizziness) to severe (i.e., pulmonary edema, cardiomyopathy, left ventricular dysfunction, hyper-
tension, cardiac arrhythmia, and myocardial infarction)20,30. These serious adverse events can occur by any route, 
but are most frequent after rapid intravenous infusion, an erroneous dose, or incorrect diluted adrenaline intra-
venous injection8,30. In our study, 2 of the 136 (all of adrenaline use before and after occurrence of hypotension) 
patients (1.5%) who received adrenaline experienced an adverse event, though neither resulted in long-lasting 
harm. Kanwar et al.30 reported a 2.4% incidence of potentially life-threatening complications from adrenaline. 
These complications were mainly from an inappropriate dose or route, but our two cases were not due to an 
incorrect dose, and the adverse events were not severe. Intramuscular, intravenous, and other routes comprised 
82%, 13%, and 5% of all adrenaline administration in our study, respectively. All major guidelines indicate intra-
muscular adrenaline as a first line treatment of anaphylaxis because of safety problem compared to intravenous 
route. Despite 2 cases of adrenaline induced adverse event in our study were not life threatening, intramuscular 
route seems safer than intravenous route. As guidelines suggest, intravenous route should be saved for those who 
require repeated dose of intramuscular adrenaline or show refractory shock despite first line treatment.
In conclusion, adrenaline use in hemodynamically stable anaphylaxis patients was associated with reduced 
risk of in-hospital occurrence of hypotension. Intramuscular adrenaline should be used as a first line treatment of 
anaphylaxis because intravenous route can trigger potentially serious adverse events.
Variables OR P value 95% CI
Use of adrenaline in 
hemodynamically stable 0.254 0.009 0.091–0.706
Table 3.  Factors associated with the development of hypotension. CI: confidence interval; OR: odds ratio.
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Methods
Study Design and Population. This incident case control study nested within a retrospective cohort study 
was conducted in the academic ED of a tertiary care, university-affiliated hospital in Seoul, Korea, that cares for 
approximately 110, 000 patients per year. Case was defined as the patients who experienced the development of 
hypotension during ED stay, and control was those who did not. Exposure of interest was adrenaline use in hemo-
dynamically stable anaphylaxis patient, confounding factors were age, sex, history of anaphylaxis and treatment 
in ED. Due to the retrospective nature of the study, our institutional review board approved the review of patient 
data before its commencement and waived the requirement for informed consent. This study was carried out in 
accordance with the approved guidelines.
Data Collection and Patient Management. The electronic medical records (EMRs) of all consecutive 
adult (≥ 16 years) patients with anaphylaxis who were hemodynamically stable (defined as systolic blood pres-
sure ≥ 90 mmHg) at presentation in the ED or other hospital area (computed tomography or magnetic reso-
nance imaging room and outpatient department) of our hospital between January 2004 and December 2013 were 
reviewed. Patient data were collected from a clinical data warehouse (CDW) which contains all EMR data. EMR 
system at ED was implemented January 2004. From the CDW, patients with discharge diagnosis of anaphylaxis 
related diseases (T780, T782, T805, T886 as ICD-10 Code) were selected and reviewed. Patients were included 
if they meet with diagnostic criteria for anaphylaxis according to the European Academy of Allergy and Clinical 
Immunology (EAACI)1,31. Two emergency physicians performed the review of medical charts together and 
reviewed the EAACI anaphylaxis guideline ahead of chart review. There were no uncertain cases for discussion.
Patients were excluded if they were younger than 16 years, did not satisfy the above definition of anaphylaxis 
or were transferred from or to other hospitals. We also excluded patients who already manifested hypotension on 
first presentation to the attending physician and/or nurse. We only used initial blood pressure checked in hospital 
and did not considered blood pressure checked in emergency medical service because such data were not stored 
in EMR database and sometime were not available even at time of ED arrival. The primary outcome was the devel-
opment of hypotension, which was defined as systolic blood pressure < 90 mmHg for more than 15 minutes with-
out signs of other causes of shock except anaphylaxis progression during ED stay. Previous studies also used this 
primary outcome as severe form of anaphylaxis32,33. Our secondary outcome of interest was in-hospital mortality.
The clinical and demographic characteristics of all patients, including their age, sex, comorbidities, initial vital 
signs, laboratory findings, in-hospital course, treatment, and clinical outcomes, were retrieved from the CDW. 
The decision to perform treatment choice such as adrenaline, other adjunctive therapy was at the discretion of 
the treating physicians.
Statistical Analysis. The data in this study were presented as the mean ± standard deviation or median 
with the interquartile range (IQR) for continuous variables and as absolute or relative frequencies for categorical 
variables. Patients who developed hypotension during ED stay were compared with those who did not. Student 
t tests or Mann-Whitney U tests were used to compare continuous variables, and chi-square tests were used for 
categorical variables. The results of logistic regression analysis of adrenaline use in hemodynamically stable ana-
phylaxis patient adjusted with age, sex and other significant factors in univariate analysis are presented as odds 
ratios (ORs) and 95% confidence intervals (CIs). A p value ≤ 0.05 was considered to be statistically significant. All 
statistical analyses were performed using SPSS for Windows version 18.0 (SPSS Inc. Chicago, IL, USA).
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